- Home
- QNST vs GYRE Comparison
QNST vs GYRE Comparison
Compare QNST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNST
- GYRE
- Stock Information
- Founded
- QNST 1999
- GYRE 2002
- Country
- QNST United States
- GYRE United States
- Employees
- QNST N/A
- GYRE N/A
- Industry
- QNST Business Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- QNST Consumer Discretionary
- GYRE Health Care
- Exchange
- QNST Nasdaq
- GYRE Nasdaq
- Market Cap
- QNST 923.2M
- GYRE 897.1M
- IPO Year
- QNST 2010
- GYRE N/A
- Fundamental
- Price
- QNST $16.18
- GYRE $7.90
- Analyst Decision
- QNST Buy
- GYRE Strong Buy
- Analyst Count
- QNST 6
- GYRE 1
- Target Price
- QNST $27.33
- GYRE $18.00
- AVG Volume (30 Days)
- QNST 561.6K
- GYRE 96.3K
- Earning Date
- QNST 11-03-2025
- GYRE 11-12-2025
- Dividend Yield
- QNST N/A
- GYRE N/A
- EPS Growth
- QNST N/A
- GYRE N/A
- EPS
- QNST 0.08
- GYRE 0.02
- Revenue
- QNST $1,093,711,000.00
- GYRE $102,189,000.00
- Revenue This Year
- QNST $10.72
- GYRE $18.39
- Revenue Next Year
- QNST $9.66
- GYRE $48.26
- P/E Ratio
- QNST $201.75
- GYRE $469.46
- Revenue Growth
- QNST 78.27
- GYRE N/A
- 52 Week Low
- QNST $14.27
- GYRE $6.11
- 52 Week High
- QNST $26.27
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- QNST 56.23
- GYRE 51.30
- Support Level
- QNST $15.64
- GYRE $7.55
- Resistance Level
- QNST $16.36
- GYRE $8.56
- Average True Range (ATR)
- QNST 0.45
- GYRE 0.51
- MACD
- QNST 0.09
- GYRE -0.01
- Stochastic Oscillator
- QNST 77.62
- GYRE 57.14
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.